What is CRVO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CRVO?

P/E (TTM) is n/a and 52-week range is $2.13 to $10.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CRVO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CRVO?

The company profile lists revenue (TTM) near $437K, net income (TTM) near $-462M, EPS (TTM) near $-3.21 when available from the market-data feed. Figures are informational and may lag live markets.

Where is CervoMed Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boston, Massachusetts, US, 13.5M shares outstanding, ISIN US15713L1098 when available from company profile and filing metadata.

CervoMed Inc

$CRVO

Health Care · Biotechnology

Run Scenarios

$3.22

-1.83%

CervoMed Inc

$CRVO

Health Care · Biotechnology

Run Scenarios

$3.22

-1.83%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

CervoMed, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 15 full-time employees. The company went IPO on 2016-11-09. The firm is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. The company focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.

Employees

15

Website

cervomed.com/

IPO

2016-11-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US15713L1098

Headquarters

Boston, Massachusetts, US

Shares outstanding

13.5M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

22.29%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

CervoMed, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 15 full-time employees. The company went IPO on 2016-11-09. The firm is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. The company focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.

Employees

15

Website

cervomed.com/

IPO

2016-11-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)